July 8, 2020Open Access

Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs

Key Points

Key points are not available for this paper at this time.

Abstract

cell lines. LC-2 demonstrates that PROTAC-mediated degradation is a viable option for attenuating oncogenic KRAS levels and downstream signaling in cancer cells.

AIに質問

Bookmark

View Full Paper

Cite This Study

Bond et al. (Wed,) studied this question.

synapsesocial.com/papers/6a0ce94e7aad2cc6fd1f6323 https://doi.org/https://doi.org/10.1021/acscentsci.0c00411

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Sos (Son of sevenless) protein1994 · 51 citations
2An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer2009 · 1,999 citations
3Bafilomycin A1 inhibits the targeting of lysosomal acid hydrolases in cultured hepatocytes1991 · 50 citations
4Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy2011 · 183 citations
5Identification of a Primary Target of Thalidomide Teratogenicity2010 · 2,089 citations

AIに質問

Bookmark

View Full Paper